Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Rigel Announces First Quarter 2015 Financial Results

PR Newswire May 7, 2015

Rigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update

PR Newswire April 30, 2015

Rigel Announces Fourth Quarter and Year End 2014 Financial Results

PR Newswire March 3, 2015

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Business Wire February 23, 2015

Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee

GlobeNewswire February 17, 2015

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

PR Newswire January 8, 2015

Rigel Announces Executive Management Changes

PR Newswire November 24, 2014

Rigel Announces Third Quarter 2014 Financial Results

PR Newswire November 4, 2014

Rigel Pharmaceuticals Inc. (RIGL) Drops 13.59% on August 13

Equities.com August 13, 2014

R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study

PR Newswire August 13, 2014

Rigel Announces Second Quarter 2014 Financial Results

PR Newswire August 5, 2014

Rigel Initiates Phase 3 Studies of Fostamatinib in ITP

PR Newswire July 16, 2014

Rigel to Present at Jefferies 2014 Global Healthcare Conference

PR Newswire May 29, 2014

Rigel Announces First Quarter 2014 Financial Results

PR Newswire May 7, 2014

Rigel Announces Webcast of Investor Day on May 6, 2014

PR Newswire April 30, 2014

Rigel Announces Publication of R118 AMPK Activator Research

PR Newswire March 6, 2014

Rigel Announces Fourth Quarter and Year End 2013 Financial Results

PR Newswire March 4, 2014

Rigel Announces Participation at Two Investor Conferences

PR Newswire February 27, 2014

Rigel Announces Participation at Two Investor Conferences

PR Newswire February 6, 2014

Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference

PR Newswire January 10, 2014